CareDx Reports Strong Preliminary Q4 & FY25 Results, Announces $88M Full-Year Share Repurchase
CDNA sits 61% above its 52-week low of $10.96.
Summary
CareDx announced robust preliminary financial results for Q4 and full-year 2025, highlighted by significant revenue growth across all segments and a substantial $88 million share repurchase program for the year.
Key Events · Earnings and Guidance · CDNA
-
Strong Revenue Growth
Preliminary Q4 2025 revenue increased 25% year-over-year to $108 million, with full-year revenue reaching $380 million, up 14% year-over-year.
-
Significant Share Repurchase
The company repurchased $88 million worth of shares during 2025, including $12 million in Q4, demonstrating a strong commitment to returning capital to shareholders.
-
Healthy Cash Position
CareDx reported approximately $200 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
-
Operational Momentum
Testing services volume increased 17% in Q4 and 14% for the full year, with patient & digital solutions revenue growing 47% in Q4.
Analysis · CDNA · Industrial Applications And Services
The preliminary financial results indicate strong operational performance for CareDx, with double-digit revenue growth in both the fourth quarter and the full year 2025. The substantial $88 million share repurchase program, representing a significant portion of the company's market capitalization, signals strong management confidence in the company's valuation and financial health. This capital allocation strategy, combined with a healthy cash position, suggests a positive outlook for the company's future performance and shareholder returns.
At the time of this filing, CDNA was trading at $17.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $885.7M. The 52-week trading range was $10.96 to $25.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.